Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Filing Type: Form 8-K (Current Report)
Date of Report: October 12, 2023
Reporting Period: Specific event date (October 12, 2023)
Business Context: The filing discloses a corporate presentation at the ROTH MKM Healthcare Opportunities Conference and a press release regarding preclinical study results for the company's candidate, Gemini.
Key Financial Metrics
This Form 8-K is a current report regarding specific events and does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
No material changes to financial position or operations are reported in this filing. The document focuses on the following non-financial events:
- Conference Presentation: The Company presented at the ROTH MKM Healthcare Opportunities Conference in New York on October 12, 2023.
- Preclinical Update: Issuance of a press release confirming that "Gemini induces pharmacologic activity and related physiologic changes in multiple preclinical studies" with key biomarker activity confirmed for evaluation in an upcoming Phase 1 study.
Guidance, Outlook, and Risks
Outlook: Management indicated that key biomarker activity for Gemini has been confirmed for evaluation in an upcoming Phase 1 study.
Regulatory Disclosure: Information contained in the presentation (Exhibit 99.1) and press release (Exhibit 99.2) is not treated as "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Risks: No specific risk factors are detailed in this 8-K text beyond the standard forward-looking nature of clinical development.
Investor Verification Checklist
- Verify the specific details of the "Gemini" preclinical study results in the attached press release (Exhibit 99.2).
- Review the corporate presentation (Exhibit 99.1) for updated timelines regarding the upcoming Phase 1 study.
- Confirm the status of the Company's cash runway and liquidity in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor for future filings regarding the initiation of the Phase 1 clinical trial.